ADMA - ADMA Biologics EPS misses by $0.02 beats on revenue

ADMA Biologics (ADMA): Q4 GAAP EPS of -$0.20 misses by $0.02.Revenue of $13.96M (+15.9% Y/Y) beats by $0.11M.At December 31, 2020, ADMA had cash and cash equivalents of $55.9 million and accounts receivable of $13.2 million.Accelerated ADMA BioCenters Plasma Collection Network Expansion Guidance; Anticipates Having 10 or More Plasma Collection Centers in Operation by 2024.Press Release

For further details see:

ADMA Biologics EPS misses by $0.02, beats on revenue